Xiaowei Zang
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Respiratory viral infections research, Cancer Treatment and Pharmacology, Neonatal Respiratory Health Research, Multiple Myeloma Research and Treatments, Pneumonia and Respiratory Infections
Most-Cited Works
- → Quantitative analysis of lab-to-lab variability in Caco-2 permeability assays(2017)92 cited
- → Prevention of paclitaxel-induced neuropathy by formulation approach(2019)47 cited
- → A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants(2024)34 cited
- → Clesrovimab for Prevention of RSV Disease in Healthy Infants(2025)28 cited
- → Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologically‐based pharmacokinetic modeling(2020)17 cited
- → Physiologically-based modeling and interspecies prediction of paclitaxel pharmacokinetics(2018)16 cited
- → Evaluation of a monoclonal antibody against respiratory syncytial virus, clesrovimab, in infants and children: Comprehensive rationale and study design for the late-stage clinical trials(2025)10 cited
- → Clesrovimab in Infants and Children at Increased Risk for Severe RSV Disease(2025)8 cited
- → Prediction of Individual Analgesic Response to Intravenous Lidocaine in Painful Diabetic Peripheral Neuropathy(2021)7 cited
- → Efficacy of monoclonal antibodies and maternal vaccination for prophylaxis of respiratory syncytial virus disease(2025)7 cited